A tissue engineering technique, referred to as autologous chondrocyte implantation (ACI), is potentially one of the most effective therapies for articular cartilage defects. However, recent clinical trials have shown no significant superiority of ACI over other surgical techniques. [1, 2]. A cause of this unexpected outcome is adverse effects resulting from the invasive procedures involved in this technique, including chondrocyte harvest, periosteal coverage, wide arthrotomy, and multiple operations. To overcome these limitations, a novel cellular implantation system without periosteal coverage, which can be arthroscopically performed, must be developed. Based on these considerations, we have established a cellular implantation system using a purified alginate gel with quite low endotoxity. The working hypothesis was that bone marrow stromal cells (BMSCs) implantation using the developed implantation system could enhance cartilage repair in osteochondral defects. The specific aims of this study were to determine the superiority of in vitro chondrogenic potential from BMSCs using the purified alginate gel compared to a commercial grade gel, and to assess reparative tissues treated with BMSCs inserted the current implantation system into cartilage defects in rabbits.
Fig. 1 The current cellular implantation system
Without any fixation, a leak of the transplanted alginate gel was prevented. The defects were divided into five groups (n=8 in each) as follows: defect, no treatment; CAlg, commercial grade alginate alone; CAlgC, commercial grade alginate with 2.5 x 10 7 BMSCs/ml; PAlg, purified alginate alone; PAlgC, purified alginate with 2.5 x 10 7 BMSCs/ml. In-vivo evaluation. At 4 and 12 weeks, the center of each defect was stained with safranin-O and H-E. The histological findings were scored with a 28-point grading scale [3] . Immunohistochemical stains were performed with anti-type I / II collagen antibodies. The mechanical properties were measured by an indentation test. Statistical Analysis: Comparison was assessed by a two-way ANOVA followed by multiple-comparison post hoc tests. P < 0.05 was considered statistically significant.
Results: In vitro study: Cell proliferation assay. From 1 to 7 days after cultivation, a significantly higher number of cells was found in the purified alginate as compared to the commercial grade alginate (p < 0.05). mRNA expressions of BMSCs. The levels of aggrecan and sox 9 genes in the purified alginate at 14 days were significantly higher than those in the commercial grade alginate (p < 0.05). Histology and Immunohistochemistry. At 21 and 28 days after cultivation, proliferated BMSCs and a newly synthesized type II collagen matrix were observed within pore spaces in the purified and commercial grade alginate gel. In vivo study: Gross morphology. The surface of the defect group was rough, depressed, and poorly integrated at 4 and 12 weeks postoperatively. In contrast, the defects of the PAlg and PAlgC groups were substituted with firm and white cartilage-like tissue at each time period. Histological findings. At 4 and 12 weeks postoperatively, residual alginate gels and inflammatory reactions were found in the CAlg and CAlgC groups. In the PAlg and PAlgC groups, no such findings were found at each time period. At 12 weeks postoperatively, the PAlgC group exhibited the nearly normal cartilaginous structures with subchondral bone structure, smooth cartilage surface, tidemark, and perfect integration. The histological scores at 12 weeks were significantly higher in the purified alginate treatment groups than in other groups (p < 0.01, the PAlgC vs other groups; the PAlg vs the defect; p < 0.05, the PAlg vs the CAlg).Overall histological score Mechanical properties. From 4 to 12 weeks postoperatively, the compression modulus of reparative tissue in the PAlgC group significantly improved (p < 0.05) and approximately reached 80% of normal.
Discussion: The current results suggest that the purification of alginate prevents immunogenic response and significantly enhances the cellular proliferation and chondrogenic differentiation of BMSCs. Our novel injectable vehicle system using a purified alginate gel provided stable implantation of BMSCs into a cartilage defect. The results of in vivo study indicate that the implantation of BMSCs using this system histologically and biomechanically enhances the reparative process of osteochondral defects. Although there are several limitations in this study, our experiments suggest a clinical possibility of arthroscopic implantation of BMSCs using the current injectable system to articular cartilaginous lesions. 
